Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP09
- Development stage
- Unknown
- Lead developer
- Aprogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
AP09 is an adalimumab biosimilar monoclonal antibody developed by Aprogen. It is a recombinant human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine that plays a central role in the inflammatory response and the pathogenesis of various autoimmune diseases. By neutralizing TNF-alpha, AP09 inhibits its binding to the p55 and p75 cell surface TNF receptors (TNFR1 and TNFR2), thereby interfering with the inflammatory signaling pathways and down-regulating the inflammatory cascade. It is being developed as a biosimilar to the reference product Humira and is currently in Phase 1 clinical trials for the treatment of autoimmune conditions.
- Other names
- Adalimumab biosimilarAprogen adalimumab biosimilar
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on AP09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP09.